Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients
Related Experiment Video
Updated: Jun 10, 2026

A Quantitative Sensory Testing Paradigm to Obtain Measures of Pain Processing in Patients Undergoing Breast Cancer Surgery
Published on: January 18, 2018
I G Kerr1, M Sone, C Deangelis
1Toronto-Bayview Regional Cancer Centre, Sunnybrook Medical Centre, Ontario, Canada.
Study Objective:
To determine the feasibility and safety of outpatient continuous narcotic infusions with additional bolus capabilities (patient-controlled analgesia) in patients with cancer pain.
Design:
A single arm (non-randomized) series.
Setting:
Outpatient with contact by telephone and through outpatient clinic.
Patients:
Consecutive series of 18 patients with poorly controlled cancer pain or significant side effects from regular administration of various narcotics.
Interventions:
Patients taught and supervised to use portable pump capable of delivering a continuous narcotic infusion with bolus capabilities.
Measurements And Main Results:
All patients had improvement in pain control as judged by the use of a linear analogue scale. Side effects and safety profile were highly acceptable. Narcotics used and maximum doses were meperidine, 50 mg/h; morphine, 80 mg/hr; and hydromorphone, 60 mg/hr. Infusion duration ranged from 7 to 225 days (mean, 54 days).
Conclusions:
Continuous narcotic infusions using a programmable portable pump with bolus capabilities is a safe and reliable method of delivering narcotics to outpatients.
Related Concept Videos
Analgesia and Pain Management
Opioid Analgesics: Morphine and Other Natural Cogeners
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Peripheral Artery Disease V: Postoperative Nursing Management

